Ligand to Report Second Quarter Results on August 4th
SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2016 financial results on August 4, 2016. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.
|
Second Quarter Earnings Call |
|||
| What: | Ligand conference call to discuss financial results and provide general business updates | ||
| When: | Thursday, August 4, 2016 | ||
| Time: | 6:00 a.m. Pacific time (9:00 a.m. Eastern time) | ||
| Conference Call: | (877) 407-4019 within the U.S. | ||
| (201) 689-8337 outside the U.S. | |||
| Passcode: Ligand | |||
| Replay Webcast: |
Conference call replay accessible at www.ligand.com |
||
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical
company focused on developing or acquiring technologies that help
pharmaceutical companies discover and develop medicines. Our business
model creates value for stockholders by providing a diversified
portfolio of biotech and pharmaceutical product revenue streams that are
supported by an efficient and low corporate cost structure. Our goal is
to offer investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk business
than a typical biotech company. Our business model is based on doing
what we do best: drug discovery, early-stage drug development, product
reformulation and partnering. We partner with other pharmaceutical
companies to leverage what they do best (late-stage development,
regulatory management and commercialization) to ultimately generate our
revenue. Ligand’s Captisol® platform technology is a
patent-protected, chemically modified cyclodextrin with a structure
designed to optimize the solubility and stability of drugs. OmniAb®
is a patent-protected transgenic animal platform used in the discovery
of fully human mono-and bispecific therapeutic antibodies. Ligand has
established multiple alliances, licenses and other business
relationships with the world's leading pharmaceutical companies
including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen,
Baxter International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160714005024/en/
Ligand Pharmaceuticals Incorporated
Todd Pettingill, (858) 550-7500
[email protected]
or
LHA
Bruce
Voss, (310) 691-7100
[email protected]
Source: Ligand Pharmaceuticals Incorporated
Released July 14, 2016